[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100431687":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients chronically infected with HPV","EXPERIMENTAL","The study will be offered to patients with chronic HPV infection as part of an annual consultation scheduled in the gynecology care package.",[13],"Procedure: Smear",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Smear","In addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Elodie Chantalat, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","5.61.32.37.51","+33","chantalat.e@chu-toulouse.fr",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":20,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"CHU Toulouse","RECRUITING","Toulouse","France","FR",{"type":39,"coordinates":40},"Point",[41,42],1.44367,43.60426,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":20,"phoneExt":20,"email":30},"Elodie Chantalat",{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100431687","multi-site-hpv-screening-by-high-throughput-sequencing-in-patients-with-chronic-hpv-hr-infection-followed-by-gynecology-100431687",false,"NCT04901351","Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology","Feasibility of a Multi-site Screening Strategy in HPV+ Patients at High Risk of Cancer, With Characterization of the HPV Subtypes Involved by High Throughput Sequencing Technique: DEP-HPV","DEP-HPV","Inclusion Criteria:\n\n-Chronic infected patients defined by: Patients with persistent HPV-HR cytological infection (high risk) (as early as 6 months post-treatment of a cervical or vaginal injury), or a recurrence of a high-grade squamous intraepithelial lesion (CIN2 or CIN3 or HSIL) or a recurrence of cancer in the cervix or vagina\n\n* Patients who have given their written consent to participate in the study.\n* Person affiliated or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\nPatient with an infection or a persistent lesion after treatment or not, linked only to low-risk HPV.","FEMALE","18 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64],"NA","The main risk of developing cervical cancer is the persistence of an High risk human papillomavirus (HPV-HR) infection, the mechanisms of which are still not understood. These chronically infected patients could develop multi-site lesions. The main objective is to assess the feasibility of setting up a personalized screening in patients at high risk of cervical cancer (chronically infected with HPV), by evaluating documenting the acceptability of these patients to be sampled from the ENT sphere and anal spheres for HPV analysis with next-generation sequencing.",[67],"Human Papillomavirus",[69,70,71,72],"Cervical cancer","Anal cancer;","ENT cancer","Next generation sequencing","2024-07-18",{"date":75,"type":76},"2024-07-19","ACTUAL",{"date":78,"type":76},"2022-06-21",{"date":80,"type":61},"2025-12",{"name":5,"class":6},1]